1. Recent Articles

    1. An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma.

      An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma.

      Oncotarget. 2018 Jun 26;9(49):29082-29096

      Authors: Tesson M, Vasan R, Hock A, Nixon C, Rae C, Gaze M, Mairs R

      Abstract Targeted radiotherapy of metastatic neuroblastoma using the somatostatin receptor (SSTR)-targeted octreotide analogue DOTATATE radiolabelled with lutetium-177 (177Lu-DOTATATE) is a promising strategy.

      Read Full Article
    2. In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

      J Control Release. 2018 Jul 03;285:162-171

      Authors: Yavuz B, Zeki J, Coburn JM, Ikegaki N, Levitin D, Kaplan DL, Chiu B

      Abstract High-risk neuroblastoma requires surgical resection and multi-drug chemotherapy. This study aimed to develop an extended release, implantable and degradable delivery system for etoposide, commonly used for neuroblastoma treatment.

      Read Full Article
    3. Correlation of CT signs with lymphatic metastasis and pathology of neuroblastoma in children.

      Correlation of CT signs with lymphatic metastasis and pathology of neuroblastoma in children.

      Oncol Lett. 2018 Aug;16(2):2439-2443

      Authors: Zhang X, Li C, Xu C, Hao X, Yu X, Li Q

      Abstract Correlation between computed tomography (CT) signs, lymphatic metastasis and pathological features of neuroblastoma (NB) in children was investigated.

      Read Full Article
      Mentions: Metastasis
    4. Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.

      Accumulation of potential driver genes with genomic alterations predicts survival of high-risk neuroblastoma patients.

      Biol Direct. 2018 Jul 16;13(1):14

      Authors: Suo C, Deng W, Vu TN, Li M, Shi L, Pawitan Y

      Abstract BACKGROUND: Neuroblastoma is the most common pediatric malignancy with heterogeneous clinical behaviors, ranging from spontaneous regression to aggressive progression.

      Read Full Article
      Mentions: MYCN
    5. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.

      Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR.

      Pediatr Blood Cancer. 2018 Jul 14;:e27354

      Authors: Druy AE, Shorikov EV, Tsaur GA, Popov AM, Zaychikov AN, Tuponogov SN, Saveliev LI, Tytgat GAM, Fechina LG

      Read Full Article
      Mentions: Bone Marrow PHOX2B
    6. Prospective investigation of applicability and the prognostic significance of bone marrow involvement in patients with neuroblastoma detected by quantitative reverse transcription PCR

      Expression of PHOX2B , TH , ELAVL4 , and B4GALNT1 (GD2‐synthase) was analyzed by quantitative polymerase chain reaction in neuroblastoma cell lines, control BM samples, and in BM samples from patients. The threshold level of expression for each gene was established through receiver operator characteristic analysis and used to determine the diagnostic test performance. The prognostic significance of BM involvement was assessed by survival rates calculations.

      Read Full Article
      Mentions: Bone Marrow PHOX2B
    7. Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase.

      Molecular Modeling for Structural Insights Concerning the Activation Mechanisms of F1174L and R1275Q Mutations on Anaplastic Lymphoma Kinase.

      Molecules. 2018 Jul 02;23(7):

      Authors: Jiang CH, Huang CX, Chen YJ, Chuang YC, Huang BY, Yang CN

      Abstract Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in various cancers. In its basal state, the structure of ALK is in an autoinhibitory form stabilized by its A-loop, which runs from the N-lobe to the C-lobe of the kinase.

      Read Full Article
      Mentions: ALK
    8. Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

      Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

      Conditions :   Childhood Solid Tumor;   Childhood Lymphoma Interventions :   Drug: Vinblastine;   Drug: Cyclophosphamide;   Drug: Capecitabine;   Drug: Nivolumab Sponsors :   Centre Oscar Lambret;   Anticancer Fund, Belgium;   Bristol-Myers Squibb Not yet recruiting

      Read Full Article
    9. Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.

      Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.

      Asia Ocean J Nucl Med Biol. 2018;6(2):161-166

      Authors: Araki R, Nishimura R, Inaki A, Wakabayashi H, Imai Y, Kuribayashi Y, Yoshimura K, Murayama T, Kinuya S

      Read Full Article
      Mentions: MIBG Chemotherapy
    10. Clinical And Epidemiological Characteristics And Survival Outcomes Of Children With Neuroblastoma: 21 Years Of Experience At The Instituto De Oncologia PediÁtrica, In SÃo Paulo, Brazil.

      CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS AND SURVIVAL OUTCOMES OF CHILDREN WITH NEUROBLASTOMA: 21 YEARS OF EXPERIENCE AT THE INSTITUTO DE ONCOLOGIA PEDIÁTRICA, IN SÃO PAULO, BRAZIL.

      Rev Paul Pediatr. 2018 Jul 10;:

      Authors: Lucena JN, Alves MTS, Abib SCV, Souza GO, Neves RPC, Caran EMM

      Read Full Article
    11. Somatic mutations in specific and connected sub-pathways are associated to short neuroblastoma patients' survival and indicate proteins targetable at onset of disease.

      Somatic mutations in specific and connected sub-pathways are associated to short neuroblastoma patients' survival and indicate proteins targetable at onset of disease.

      Int J Cancer. 2018 Jul 11;:

      Authors: Esposito MR, Binatti A, Pantile M, Coppe A, Mazzocco K, Longo L, Capasso M, Lasorsa VA, Luksch R, Bortoluzzi S, Tonini GP

      Read Full Article
    12. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

      Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

      Br J Cancer. 2018 Jul 11;:

      Authors: Berthold F, Ernst A, Hero B, Klingebiel T, Kremens B, Schilling FH, Simon T

      Read Full Article
      Mentions: GPOH Chemotherapy
    13. EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, Qarziba®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma

      EUSA Pharma: NICE Approves the Targeted Cancer Immunotherapy, Qarziba®▼ (dinutuximab beta) to Treat Children with High-Risk Neuroblastoma

      HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--EUSA Pharma today welcomed a decision by the National Institute for Health and Care Excellence (NICE) to recommend the use of the targeted cancer immunotherapy, QARZIBA® (dinutuximab beta) to treat children with high-risk neuroblastoma within the NHS in England and Wales.i High-risk neuroblastoma is an aggressive form of neuroblastoma – the most common solid tumour of childhood that originates outside of the brain.ii Dinutuximab beta is the first targe

      Read Full Article
    14. See all articles
  2. Comments

  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Topics in the News

    1. (6 articles) MYCN
    2. (4 articles) Treatment
    3. (4 articles) Chemotherapy
    4. (3 articles) Immunotherapy
    5. (3 articles) Metastasis
  3. Recent Quotes

    1. We continue to expand our broad array of proprietary T cell programming technologies designed to tackle specific aspects of tumour biology and we are pleased to highlight the article published in Molecular Therapy about our novel small-molecule-activated permanent off switch.
      By Christian Itin
    2. We wanted to remove an important barrier in using B cells as an antigen-presenting cell population, helping them complement or replace dendritic cells.
      By Gregory Szeto
    3. The antigen-presenting capabilities of B cells have often been underestimated, but they are being increasingly appreciated for their practical advantages in therapies.
      By Gail Bishop
    4. Our dream is to spawn out a whole class of therapies which involve taking out your own cells, telling them what to do, and putting them back into your body to fight your disease, whatever that may be.
      By Armon Sharei
    5. We envision a future system, if we can take advantage of its microfluidic nature, as a bedside or field-deployable device.
      By Armon Sharei
    6. Down the road, you could potentially get enough cells from just a normal syringe-based blood draw, run it through a bedside device that has the antigen you want to vaccinate against, and then you'd have the vaccine.
      By Gregory Szeto
    7. The problem is that unlike blood, a skin sample or even a tissue biopsy, you can't take a piece of a patient's neural system. It runs like complex wiring throughout the body and portions cannot be sampled for study.
      By Mick Bhatia
    8. Now we can take easy to obtain blood samples, and make the main cell types of neurological systems - the central nervous system and the peripheral nervous system - in a dish that is specialized for each patient.
      By Mick Bhatia
    9. If I was a patient and I was feeling pain or experiencing neuropathy, the prized pain drug for me would target the peripheral nervous system neurons, but do nothing to the central nervous system, thus avoiding non-addictive drug side effects.
      By Mick Bhatia
    10. This bench to bedside research is very exciting and will have a major impact on the management of neurological diseases, particularly neuropathic pain.
      By Akbar Panju